Abbvie Plc was Ironwood Pharmaceuticals’s largest product and service line in fiscal 2025, bringing in $289.32M of $293.02M (99%).
| Product and Service | FY 2013 | FY 2014 | FY 2015 | FY 2017 | FY 2018 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Abbvie Plc | $398.77M | $430.46M | $340.39M | $289.32M | |||||
| Abbvie | — | — | — | — | |||||
| Allergan | — | — | — | — | |||||
| Allergan (North America) | — | — | — | — | |||||
| Astellas Pharma Inc | $2.00M | $1.80M | $1.67M | $1.69M | |||||
| Astellas | — | — | — | — | |||||
| Astellas (Japan) | — | — | — | — | |||||
| Almirall | — | — | — | — | |||||
| Almirall (Europe) | — | — | — | — | |||||
| Exact Sciences | — | — | — | — | |||||
| Alnylam | $2.20M | — | — | — | |||||
| Asahi Kasei Pharma Corporation | — | $2.01M | $2.25M | — | |||||
| Astellas Pharma Inc., 2009 License Agreement, Amended 2019 | $2.00M | $1.80M | $1.70M | $1.70M | |||||
| Astrazeneca | $635.00K | $430.00K | $400.00K | $321.00K | |||||
| Astrazeneca (China, Hong Kong & Macau) | — | — | — | — | |||||
| Total | $405.60M | $436.50M | $346.42M | $293.02M |
Ironwood Pharmaceuticals brought in $293.02M from its four product and service lines in fiscal 2025, the year ended December 31, 2025. Ironwood Pharmaceuticals regrouped these lines after fiscal 2024, so the total does not compare directly with that year's $346.42M. Abbvie Plc was the largest at $289.32M (98.7%), ahead of Astellas Pharma Inc., 2009 License Agreement, Amended 2019 at $1.70M (0.6%) and Astellas Pharma Inc at $1.69M (0.6%). The remaining line, Astrazeneca, brought in $321.00K.
Ironwood Pharmaceuticals stopped reporting Asahi Kasei Pharma Corporation ($2.25M in fiscal 2024) and Alnylam ($2.20M in fiscal 2022) as separate lines.
Collaborative Arrangements, Linzess was Ironwood Pharmaceuticals’s largest product and service line in fiscal 2025, bringing in $289.32M of $295.83M (98%).
| Product and Service | FY 2014 | FY 2015 | FY 2016 | FY 2018 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|
| Collaborative Arrangements, Linzess | $398.77M | $430.46M | $340.39M | $289.32M | ||||
| Linaclotide | — | — | — | — | ||||
| Sale Of Active Pharmaceutical Ingredient | — | — | — | — | ||||
| Cologuard | — | — | — | — | ||||
| Royalty | $4.90M | $4.60M | $4.50M | $4.74M | ||||
| Collaborative Arrangement, Co-Promotion Agreements | — | $2.01M | $2.25M | — | ||||
| Collaborative Arrangement, Promotion Agreements | — | — | — | — | ||||
| Collaborative Arrangement, Collaboration & License Agreements | $4.45M | $4.58M | $1.67M | $1.69M | ||||
| Collaborative Arrangement, Development & Commercialization Agreements | — | $2.00M | — | — | ||||
| Product Revenue, Net | — | — | — | — | ||||
| Collaborative Arrangement, Other Agreements | $1.82M | $2.48M | $734.00K | $87.00K | ||||
| Viberzi | — | — | — | — | ||||
| Total | $409.94M | $446.13M | $349.55M | $295.83M |
Ironwood Pharmaceuticals brought in $295.83M from its four product and service lines in fiscal 2025, the year ended December 31, 2025. Ironwood Pharmaceuticals regrouped these lines after fiscal 2024, so the total does not compare directly with that year's $349.55M. Collaborative Arrangements, Linzess was the largest at $289.32M (97.8%), ahead of Royalty at $4.74M (1.6%) and Collaborative Arrangement, Collaboration & License Agreements at $1.69M (0.6%). The remaining line, Collaborative Arrangement, Other Agreements, brought in $87.00K.
From fiscal 2022 to 2025, combined revenue from these lines fell from $409.94M to $295.83M, a compound annual decline of 10.3%. Collaborative Arrangements, Linzess' share of the total rose from 97.3% to 97.8%.
Ironwood Pharmaceuticals stopped reporting Collaborative Arrangement, Co-Promotion Agreements ($2.25M in fiscal 2024) and Collaborative Arrangement, Development & Commercialization Agreements ($2.00M in fiscal 2023) as separate lines.
North America was Ironwood Pharmaceuticals’s largest region in fiscal 2025, bringing in $289.32M of $295.92M (98%).
| Geography | FY 2014 | FY 2015 | FY 2017 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|
| North America | $401.50M | $433.24M | $340.39M | $289.32M | ||||
| Japan | — | — | — | — | ||||
| Europe | — | — | — | — | ||||
| Canada & Mexico | $2.70M | $2.80M | $2.80M | $3.00M | ||||
| Europe & Other | $2.44M | $2.80M | $3.24M | $3.60M | ||||
| China, Hong Kong, & Macau | — | — | — | — | ||||
| Total | $406.64M | $438.84M | $346.43M | $295.92M |
Ironwood Pharmaceuticals brought in $295.92M from its three regions in fiscal 2025, the year ended December 31, 2025. That was down 14.6% from $346.43M in fiscal 2024. North America was the largest at $289.32M (97.8%), ahead of Europe & Other at $3.60M (1.2%) and Canada & Mexico at $3.00M (1.0%).
From fiscal 2022 to 2025, combined revenue from these regions fell from $406.64M to $295.92M, a compound annual decline of 10.1%. North America's share of the total fell from 98.7% to 97.8%.
Ironwood Pharmaceuticals (IRWD) reports its revenue by product and service and by geography. In fiscal 2025, Abbvie Plc was its largest product and service line, bringing in $289.32M (98.7% of the total), followed by Astellas Pharma Inc., 2009 License Agreement, Amended 2019 at $1.70M (0.6%).
Abbvie Plc was Ironwood Pharmaceuticals' largest product and service line in fiscal 2025, bringing in $289.32M, or 98.7% of the $293.02M total across its four product and service lines.
North America was Ironwood Pharmaceuticals' largest region in fiscal 2025, bringing in $289.32M, or 97.8% of the $295.92M total across its three regions.
Every figure comes from Ironwood Pharmaceuticals' annual financial filings, as reported. Each line keeps the name Ironwood Pharmaceuticals gives it, and years follow its fiscal calendar.
Ironwood Pharmaceuticals' revenue by product and service goes back to fiscal 2013, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.